Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour
Information source: Centre Hospitalier Universitaire Vaudois
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Preterm Labor
Intervention: Nifedipine (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Chantal Csajka Official(s) and/or principal investigator(s): Alice Panchaud, PhD, Principal Investigator, Affiliation: Centre Hospitalier Universitaire Vaudois
Overall contact: Alice Panchaud, PhD, Phone: 0213144276, Ext: +41, Email: Alice.Panchaud@chuv.ch
Summary
Preterm birth is the leading cause of perinatal mortality and morbidity. According to WHO,
15 million children are born prematurely (gestational age < 37 weeks) in the world each year
while 7% of them die because of complications associated with prematurity. Despite constant
improvement of obstetrical care, the number of preterm births has increased over the last
decades and prematurity is still the most frequent cause of prenatal hospitalization in
industrialized countries.
The American College of Obstetricians and Gynecologists as well as the Royal College of
Obstetricians and Gynaecologists recommend nifedipine as a first-line tocolytic in case of
acute threatened preterm labour. Clinical experience show however an important variability
in treatment response among pregnant women. In spite of its large use in obstetrics as a
tocolytic agent, nifedipine is prescribed off-label. As a consequence no international
consensus on optimal dose schedule has so far been proposed.
Small sample size and heterogeneousness of tocolysis administration protocols make it
difficult to compare the little data available on the pharmacokinetics of nifedipine in
pregnant women. Nevertheless an important interindividual variability in concentrations has
been identified (CV=12-76%) but very few studies have investigated the possible reasons of
this variability in pregnant women. Genetic and environmental factors involved in drug
distribution and metabolism (e. g. enzymatic activity, CYP 3A5 genotype) might partially
explain variability in drug levels and therefore differences in treatment response.
The goal of this study is to quantify the variability in nifedipine pharmacokinetics and
identify potential genetic and non-genetic sources of variability in nifedipine
pharmacokinetics in pregnant women. The relationship between concentration and treatment
response will be evaluated and will serve to propose optimal dosage regimen to improve
efficacy and reduce side effects associated with this treatment.
Clinical Details
Official title: Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Patients Hospitalized for Acute Threatened Preterm Labour
Study design: Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Nifedipine blood concentrationGenotyping Phenotyping
Secondary outcome: Nifedipine side effects (feeling)Maternal heart rate (measurement) Maternal blood pressure (measurement) Fetal heart rate (measurement) Uterine contraction (measurement) Uterine contraction (feeling) Birth date
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Pregnant women under nifedipine treatment for acute threatened preterm labour
- Hospitalization for this condition in the maternity of the University Hospital of
Lausanne (CHUV)
- Gestational age of 20-34 weeks
- Signed informed consent
Exclusion Criteria:
- Patient < 18 years
- Contraindication to tocolysis for clinical reasons (e. g. severe pre-eclampsia,
chorioamnionitis, placental anomaly, letal fetal anomaly, important intrauterine
growth restriction) or current labour
- Contraindication to nifedipine
- Severe renal or hepatic impairment
- Fever > 37. 5°C
- Incapacity of communication
Locations and Contacts
Alice Panchaud, PhD, Phone: 0213144276, Ext: +41, Email: Alice.Panchaud@chuv.ch
Centre Hospitalier Universitaire Vaudois, Lausanne, Vaud 1011, Switzerland; Recruiting Alice Panchaud, PhD, Phone: 0213144276, Ext: +41, Email: Alice.Panchaud@chuv.ch Alice Panchaud, PhD, Principal Investigator David Baud, MD PhD MER, Sub-Investigator Chantal Csajka, Prof PhD, Sub-Investigator Chin B Eap, Prof PhD, Sub-Investigator Karine Lepigeon, Sub-Investigator Etienne Weisskopf, PharmD, Sub-Investigator
Additional Information
Starting date: April 2014
Last updated: July 27, 2015
|